Financings in Brief: Aurora Biosciences
This article was originally published in The Gray Sheet
Aurora Biosciences: Drug discovery system firm goes public in an offering of 4 mil. shares for $10 each. Aurora, based in La Jolla, California, says it will use proceeds to fund "working capital and general corporate purposes, including enhancement of research and development capabilities, the acquisition of chemical libraries, and facilities expansion and improvements." Alex. Brown served as lead underwriter for the offering; Hambrecht & Quist and Robertson, Stephens were co-managers. Underwriters hold an over-allotment option to buy 600,000 additional shares...
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.